Ospedale Pediatrico Bambino Gesu — Sponsor Intelligence | 12 EU Trials

Filter these 12 trials by condition, phase, country and more.

Open in Search →

12 Registered trials

8 Recruiting

3 Completed trials

9 Countries active

26 Unique IMPs

100% Results reported

Phase III

Phase II

Phase I (FiH)

Phase III: 2 Phase II/III: 1 Phase II: 4 Phase I: 1 Phase I (Other): 1 Phase I (FiH): 3

100%

3 of 3 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Dent's disease 1 T-cell lymphoma 1 Nephrotic syndrome 1

Top IMPs

CYCLOPHOSPHAMIDE 3 FLUDARABINE PHOSPHATE 3 AUTOLOGOUS T CELLS TRANSDUCED WITH A RETROVIRAL VECTOR ENCODING A CHIMERIC ANTIGEN RECEPTOR AGAINST GD2, EX-VIVO EXPANDED 2 RIMIDUCID 2 ALPELISIB 1 ANTI-T LYMPHOCYTE IMMUNOGLOBULIN FOR HUMAN USE, RABBIT 1 AUTOLOGOUS T-CELLS TRANSDUCED WITH LENTIVIRAL VECTOR EXPRESSING A CHIMERIC ANTIGEN RECEPTOR DIRECTED AGAINST CD19 1 BLINATUMOMAB 1 BUMETANIDE 1 BUSULFAN 1 CD19-CAR_LENTI_ALLO 1 CD7-CART01 1

All trials

12 total

The MEMORINEPH study: Memory B cell level-based tailored treatment with Rixathon in children with complicated forms of steroid-sensitive Nep… Not authorised

2024-511214-20-00 Phase II 1 country RITUXIMAB
Framework for Optimizing, Refining, and Unifying Management of HSCT in Pediatric ALL. Recruiting

2025-522052-13-00 Phase II/III 9 countries ANTI-T LYMPHOCYTE IMMUNOGLOBULIN FOR HUMAN USE, RABBIT; BLINATUMOMAB; BUSULFAN; …
EArly adminiStration of Ivabradine in CHILDren with heart failure Recruiting

2025-520916-32-00 Phase II 1 country IVABRADINE HYDROCHLORIDE
A no-profit, open-label, phase II pilot study on the efficacy and safety of Alpelisib in patients with Dent 2 disease (ALPEDENT study) Recruiting

2024-514196-17-00 Phase II 1 country ALPELISIB; DIMERCAPTOSUCCINIC ACID
Phase I/II study of anti-GD2 Chimeric Antigen Receptor-Expressing T cells in pediatric patients affected by High Risk and/or relapsed/refrac… Recruiting

2024-520436-15-00 Phase I (FiH) 1 country AUTOLOGOUS T CELLS TRANSDUCED WITH A RETROVIRAL VECTOR ENCODING A CHIMERIC ANTIG…
Phase I study of anti-GD2 Chimeric Antigen Receptor-Expressing T cells in pediatric and young adult patients affected by relapsed/refractory… Recruiting

2024-519168-42-00 Phase I (Other) 1 country AUTOLOGOUS T CELLS TRANSDUCED WITH A RETROVIRAL VECTOR ENCODING A CHIMERIC ANTIG…
Phase I clinical trial on the use of fresh, allogeneic, second-generation CD19-CAR T cells for treatment of children and young adult with re… Recruiting

2023-508420-36-00 Phase I 1 country CD19-CAR_LENTI_ALLO; CYCLOPHOSPHAMIDE; FLUDARABINE PHOSPHATE
Phase I/II study of anti-CD7 Chimeric Antigen Receptor-Expressing T cells in pediatric patients/young adult affected by relapsed/refractory… Recruiting

2023-508355-39-00 Phase I (FiH) 1 country CD7-CART01; CYCLOPHOSPHAMIDE; FLUDARABINE PHOSPHATE
Assessing the efficacy of Bumetanide for the improvement of cognitive functions in children and adolescents with Down syndrome Recruiting

2024-519342-71-00 Phase II 1 country BUMETANIDE
CD19-CAR_Lenti in pediatric patients affected by relapsed/refractory B-ALL or aggressive B-NHL Ended

2024-519174-39-00 Phase I (FiH) 1 country AUTOLOGOUS T-CELLS TRANSDUCED WITH LENTIVIRAL VECTOR EXPRESSING A CHIMERIC ANTIG…
The Italian Cohort (ITACO) and the Analytical Antiretroviral Treatment Interruption Italian Cohort (ITACO-ATI) study guided by molecular HIV… Ended

2024-518694-33-00 Phase III 1 country
Double-blind, randomized, monocentric study to evaluate the efficacy and safety of memantine in adolescents with Bipolar Disorder Ended

2024-516713-21-00 Phase III 1 country MEMANTINE HYDROCHLORIDE

Showing 1–12 of 12 trials

← All sponsors A–Z